Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04256681
Other study ID # GIP 595
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 30, 2018
Est. completion date May 31, 2021

Study information

Verified date November 2021
Source IRCCS Eugenio Medea
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Self-Notion and Perception (SNAP) questionnaire developed at IRCCS E.Medea by Eleonora Diella and Roberta Morganti, arises from the need to quantify the subjective perception of the patient suffering from HSP of the typical symptoms of pathology, such as spasticity, weakness, changes in balance, resistance in walking, pain and fatigue. The purpose of this study is to validate this instrument and test its reliability, looking for correlations with the measurement scales used in the literature for the evaluation of the patient with HSP. The most used for this population are the Spastic Paraplegia Rating Scale (SPRS) and the Six-Minute Walk Test (6MWT) which assess the severity of the disease and the level of endurance (8-9) respectively.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date May 31, 2021
Est. primary completion date May 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 9 Years and older
Eligibility Inclusion Criteria: - diagnosis of genetically determined hereditary spastic paraparesis or subjects without defined genetics but who unequivocally show at the time of evaluation a dominant or recessive familiarity with exclusive involvement of the pyramidal system - age> 9 years - IQ> 80 - The patient must be able to walk for at least 10 meters. Indoors, even with help Exclusion Criteria: - Age less than 9 years - IQ <80, - loss of gait - psychopathological aspects that can affect the validity of the data collected

Study Design


Intervention

Other:
SNAP questionnaire
The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.

Locations

Country Name City State
Italy Eleonora Diella Bosisio Parini

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Eugenio Medea

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Test the validity, investigating the correlation with Spastic Paraplegia Rating Scale and with Six-Minute Walk Test, and the reliability (through test-retest mode) of the SNAP questionnaire in the aforementioned population. the Spastic Paraplegia Rating Scale (SPRS) and the Six-Minute Walk Test (6MWT) which assess the severity of the disease and the level of endurance respectively. 2 days
See also
  Status Clinical Trial Phase
Completed NCT04768166 - Testing Miglustat Administration in Subjects With Spastic Paraplegia 11 Phase 2
Recruiting NCT06229626 - Evaluation of an Intensive Training Program for Patients With Hereditary Spastic Paraparesis SPG4/Spast N/A
Completed NCT00677768 - Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) N/A